Tax-driven share sale by SOPHiA GENETICS (SOPH) CEO Jurgi Camblong

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 ordinary shares in an open-market transaction at a weighted average price of $4.7727 per share. The sale was executed to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. Following this transaction, Camblong directly holds 3,302,839 ordinary shares.

Insider Trade Summary 10b5-1

Net Seller: 4,486 shares ($21,410)

Net Sell 1 txn

Insider Camblong Jurgi

Role Chief Executive Officer

Sold 4,486 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	4,486	$4.7727	$21K

Holdings After Transaction: Ordinary Shares — 3,302,839 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.68 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		4,486(1)	D	$4.7727(2)	3,302,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.68 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for CEO Jurgi Camblong?

CEO Jurgi Camblong sold 4,486 ordinary shares of SOPHiA GENETICS in an open-market transaction at a weighted average price of $4.7727 per share, according to a Form 4 insider trading report.

Why did the SOPHiA GENETICS CEO sell 4,486 shares according to the Form 4 filing?

The shares were sold to satisfy tax obligations from restricted stock units that vested on March 18, 2026. The filing notes these tax-related sales were executed under a pre-established Rule 10b5-1 trading plan.

Were the SOPHiA GENETICS CEO’s share sales discretionary trades?

No. The Form 4 states the sales were made under a pre-established Rule 10b5-1 trading plan and specifically notes they do not represent discretionary trades by the CEO, indicating they were pre-planned for tax purposes.

What price range did the SOPHiA GENETICS CEO’s share sales cover?

The reported weighted average sale price was $4.7727 per share. Footnotes explain the shares were sold in multiple transactions at prices ranging from $4.68 to $4.87 per share, with detailed breakdowns available on request.

How many SOPHiA GENETICS shares does CEO Jurgi Camblong hold after this transaction?

After selling 4,486 ordinary shares, CEO Jurgi Camblong directly holds 3,302,839 ordinary shares of SOPHiA GENETICS, as disclosed in the Form 4 under total shares following the reported transaction.

What is the significance of the Rule 10b5-1 plan mentioned in SOPHiA GENETICS’ Form 4?

The filing states the CEO’s sales were made under a pre-established Rule 10b5-1 trading plan. Such plans schedule trades in advance, showing these transactions were structured and tax-related rather than opportunistic market timing decisions.